Evidence map›Paper›PMID 35410113›Full record

ArticleCancer research and treatment2023

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer.

Jihoon Kang, Ji-Young Lee, Sunmin Lee, Danbee Kim, Jinyeong Lim, Ha Ra Jun, Seyeon Jeon, Young-Ae Kim, Hye Seon Park, Kyu-Pyo Kim and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jihoon KangDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ji-Young LeeDepartment of Medical Science, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, Korea.
Sunmin LeeUniversity of Ulsan Digestive Diseases Research Center, Seoul, Korea.
Danbee KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jinyeong LimCenter for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, Seoul, Korea.
Ha Ra JunCenter for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, Seoul, Korea.
Seyeon JeonDepartment of Medical Science, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, Korea.
Young-Ae KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hye Seon ParkDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kyu-Pyo KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sung-Min ChunCenter for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, Seoul, Korea.
Hee Jin LeeDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Changhoon YooDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Asan Medical Center · KRUlsan College · KRUniversity of Ulsan · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2020IP0091-1Ministry of Science ICT and Future Planning 2016M3A9E8941331Ministry of Science ICT and Future Planning 2017M3A9G5061671Ministry of Science ICT and Future Planning 2019R1F1A1061436National Research Foundation of Korea
6 · The paper itself

Abstract

purposeBiliary tract cancers (BTCs) are rare and show a dismal prognosis with limited treatment options. To improve our understanding of these heterogeneous tumors and develop effective therapeutic agents, suitable preclinical models reflecting diverse tumor characteristics are needed. We established and characterized new patient-derived cancer cell cultures and patient-derived xenograft (PDX) models using malignant ascites from five patients with BTC. MATERIALS AND

methodsFive patient-derived cancer cell cultures and three PDX models derived from malignant ascites of five patients with BTC, AMCBTC-01, -02, -03, -04, and -05, were established. To characterize the models histogenetically and confirm whether characteristics of the primary tumor were maintained, targeted sequencing and histopathological comparison between primary tissue and xenograft tumors were performed.

resultsFrom malignant ascites of five BTC patients, five patient-derived cancer cell cultures (100% success rate), and three PDXs (60% success rate) were established. The morphological characteristics of three primary xenograft tumors were compared with those of matched primary tumors, and they displayed a similar morphology. The mutated genes in samples (models, primary tumor tissue, or both) from more than one patient were TP53 (n=2), KRAS (n=2), and STK11 (n=2). Overall, the pattern of commonly mutated genes in BTC cell cultures was different from that in commercially available BTC cell lines.

conclusionWe successfully established the patient-derived cancer cell cultures and xenograft models derived from malignant ascites in BTC patients. These models accompanied by different genetic characteristics from commercially available models will help better understand BTC biology.

Indexed as

AscitesBiliary Tract NeoplasmsAnimalsCell Culture TechniquesHeterograftsHumansPrognosisAscitesBiliary tract neoplasmsCancer cell culturesHigh-throughput nucleotide sequencingPatient-derived xenograft

Identifiers

PMID35410113
PMCPMC9873337
OpenAlexW4223429885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.